Poland, Romania, the Russian Federation,Slovakia, South Africa, Spain, Taiwan, Turkey,the United Kingdom, and the United States). References 1. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia intype 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the AmericanDiabetes Association and the EuropeanAssociation for the Study of Diabetes. Diabetes Care 2009;32:193 –203 2. Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [cor- rected] Study Group. Ef ﬁcacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double- blind, randomized trial. J Clin EndocrinolMetab 2004;89:6068 –6076 3. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with met- formin on glycemic control and indicators of insulin sensitivity in recently diagnosedpatients with type 2 diabetes. J Clin Endo- crinol Metab 2003;88:1637 –1645